Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + disitamab vedotin for HER2-expressing metastatic colorectal cancer after at least two prior systemic treatment lines
ChiCTR2200062770Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and disitamab vedotin in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective response rate. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
pembrolizumabdisitamab vedotin
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2200062770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062770.